99 related articles for article (PubMed ID: 25016819)
1. [Mechanisms of resistance to molecular targeted drugs].
Fujita N
Nihon Rinsho; 2014 Jun; 72(6):1151-6. PubMed ID: 25016819
[TBL] [Abstract][Full Text] [Related]
2. Understanding resistance to targeted cancer drugs through loss of function genetic screens.
Berns K; Bernards R
Drug Resist Updat; 2012 Oct; 15(5-6):268-75. PubMed ID: 23142522
[TBL] [Abstract][Full Text] [Related]
3. Mechanisms of intrinsic and acquired resistance to kinase-targeted therapies.
Bagrodia S; Smeal T; Abraham RT
Pigment Cell Melanoma Res; 2012 Nov; 25(6):819-31. PubMed ID: 22883054
[TBL] [Abstract][Full Text] [Related]
4. Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis.
Yauch RL; Settleman J
Curr Opin Genet Dev; 2012 Feb; 22(1):45-9. PubMed ID: 22321987
[TBL] [Abstract][Full Text] [Related]
5. Primary and acquired resistance to anti-EGFR targeted drugs in cancer therapy.
Morgillo F; Bareschino MA; Bianco R; Tortora G; Ciardiello F
Differentiation; 2007 Nov; 75(9):788-99. PubMed ID: 17608727
[TBL] [Abstract][Full Text] [Related]
6. Making progress through molecular attacks on cancer.
Sawyers CL
Cold Spring Harb Symp Quant Biol; 2005; 70():479-82. PubMed ID: 16869786
[TBL] [Abstract][Full Text] [Related]
7. Sphingolipids and response to chemotherapy.
Dimanche-Boitrel MT; Rebillard A
Handb Exp Pharmacol; 2013; (216):73-91. PubMed ID: 23563652
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of acquired resistance to targeted cancer therapies.
Lackner MR; Wilson TR; Settleman J
Future Oncol; 2012 Aug; 8(8):999-1014. PubMed ID: 22894672
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.
Izar B; Rotow J; Gainor J; Clark J; Chabner B
Pharmacol Rev; 2013; 65(4):1351-95. PubMed ID: 24092887
[TBL] [Abstract][Full Text] [Related]
10. Targeting cancer with small-molecular-weight kinase inhibitors.
Fabbro D; Cowan-Jacob SW; Möbitz H; Martiny-Baron G
Methods Mol Biol; 2012; 795():1-34. PubMed ID: 21960212
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy.
Bianco R; Troiani T; Tortora G; Ciardiello F
Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S159-71. PubMed ID: 16113092
[TBL] [Abstract][Full Text] [Related]
12. Somatic alterations as the basis for resistance to targeted therapies.
Blair BG; Bardelli A; Park BH
J Pathol; 2014 Jan; 232(2):244-54. PubMed ID: 24114654
[TBL] [Abstract][Full Text] [Related]
13. [Driver gene mutation and targeted therapy of lung cancer].
Mitsudomi T
Gan To Kagaku Ryoho; 2013 Mar; 40(3):285-90. PubMed ID: 23507588
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor: pathway, therapies, and pipeline.
Goffin JR; Zbuk K
Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
[TBL] [Abstract][Full Text] [Related]
15. Intrinsic and acquired drug resistance in malignant tumors. The main reason for therapeutic failure.
Lippert TH; Ruoff HJ; Volm M
Arzneimittelforschung; 2008; 58(6):261-4. PubMed ID: 18677966
[TBL] [Abstract][Full Text] [Related]
16. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
17. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
Oxnard GR
Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
[TBL] [Abstract][Full Text] [Related]
18. Dominant mechanisms of primary resistance differ from dominant mechanisms of secondary resistance to targeted therapies.
Asić K
Crit Rev Oncol Hematol; 2016 Jan; 97():178-96. PubMed ID: 26364890
[TBL] [Abstract][Full Text] [Related]
19. [Historical aspect of molecular-targeted therapy for cancer].
Sone S; Otsuka K; Tobiume M; Tada H
Nihon Rinsho; 2010 Oct; 68(10):1787-95. PubMed ID: 20954319
[TBL] [Abstract][Full Text] [Related]
20. Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance.
Selvam SP; Ogretmen B
Handb Exp Pharmacol; 2013; (216):3-27. PubMed ID: 23563649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
